These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 27493187)

  • 41. A boronic-chalcone derivative exhibits potent anticancer activity through inhibition of the proteasome.
    Achanta G; Modzelewska A; Feng L; Khan SR; Huang P
    Mol Pharmacol; 2006 Jul; 70(1):426-33. PubMed ID: 16636137
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Myocyte-Damaging Effects and Binding Kinetics of Boronic Acid and Epoxyketone Proteasomal-Targeted Drugs.
    Hasinoff BB; Patel D
    Cardiovasc Toxicol; 2018 Dec; 18(6):557-568. PubMed ID: 29951728
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Synthesis and biological evaluation of curcumin derivatives modified with α-amino boronic acid as proteasome inhibitors.
    Zhang W; Bai H; Han L; Zhang H; Xu B; Cui J; Wang X; Ge Z; Li R
    Bioorg Med Chem Lett; 2018 Aug; 28(14):2459-2464. PubMed ID: 29886021
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [The proteasome - structural aspects and inhibitors: a second life for a validated drug target].
    Reboud-Ravaux M
    Biol Aujourdhui; 2021; 215(1-2):1-23. PubMed ID: 34397372
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Discovery and development of second-generation proteasome inhibitors.
    Kirk CJ
    Semin Hematol; 2012 Jul; 49(3):207-14. PubMed ID: 22726543
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Design, synthesis and docking studies of novel dipeptidyl boronic acid proteasome inhibitors constructed from αα- and αβ-amino acids.
    Shi J; Lei M; Wu W; Feng H; Wang J; Chen S; Zhu Y; Hu S; Liu Z; Jiang C
    Bioorg Med Chem Lett; 2016 Apr; 26(8):1958-62. PubMed ID: 26965867
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Proteasome inhibitors.
    Cvek B
    Prog Mol Biol Transl Sci; 2012; 109():161-226. PubMed ID: 22727422
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Clinical Pharmacology of Ixazomib: The First Oral Proteasome Inhibitor.
    Gupta N; Hanley MJ; Xia C; Labotka R; Harvey RD; Venkatakrishnan K
    Clin Pharmacokinet; 2019 Apr; 58(4):431-449. PubMed ID: 30117017
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Structural Basis for the Species-Selective Binding of N,C-Capped Dipeptides to the Mycobacterium tuberculosis Proteasome.
    Hsu HC; Singh PK; Fan H; Wang R; Sukenick G; Nathan C; Lin G; Li H
    Biochemistry; 2017 Jan; 56(1):324-333. PubMed ID: 27976853
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Probing the anticancer mechanism of prospective herbal drug Withaferin A on mammals: a case study on human and bovine proteasomes.
    Grover A; Shandilya A; Bisaria VS; Sundar D
    BMC Genomics; 2010 Dec; 11 Suppl 4(Suppl 4):S15. PubMed ID: 21143798
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Boron chemicals in diagnosis and therapeutics.
    Das BC; Thapa P; Karki R; Schinke C; Das S; Kambhampati S; Banerjee SK; Van Veldhuizen P; Verma A; Weiss LM; Evans T
    Future Med Chem; 2013 Apr; 5(6):653-76. PubMed ID: 23617429
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Systematic comparison of peptidic proteasome inhibitors highlights the α-ketoamide electrophile as an auspicious reversible lead motif.
    Stein ML; Cui H; Beck P; Dubiella C; Voss C; Krüger A; Schmidt B; Groll M
    Angew Chem Int Ed Engl; 2014 Feb; 53(6):1679-83. PubMed ID: 24403024
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Discovery of a novel dipeptidyl boronic acid proteasome inhibitor for the treatment of multiple myeloma and triple-negative breast cancer.
    Lei M; Feng H; Bai E; Zhou H; Wang J; Qin Y; Zhang H; Wang X; Liu Z; Hai O; Liu J; Zhu Y
    Org Biomol Chem; 2019 Jan; 17(3):683-691. PubMed ID: 30601533
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Development and Application of a Sensitive Peptide Reporter to Discover 20S Proteasome Stimulators.
    Coleman RA; Trader DJ
    ACS Comb Sci; 2018 May; 20(5):269-276. PubMed ID: 29553711
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Selected cytotoxic gold compounds cause significant inhibition of 20S proteasome catalytic activities.
    Micale N; Schirmeister T; Ettari R; Cinellu MA; Maiore L; Serratrice M; Gabbiani C; Massai L; Messori L
    J Inorg Biochem; 2014 Dec; 141():79-82. PubMed ID: 25217719
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Oral proteasome inhibitor with strong preclinical efficacy in myeloma models.
    Park J; Park E; Jung CK; Kang SW; Kim BG; Jung Y; Kim TH; Lim JY; Lee SE; Min CK; Won KA
    BMC Cancer; 2016 Mar; 16():247. PubMed ID: 27012957
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Novel cell line models to study mechanisms and overcoming strategies of proteasome inhibitor resistance in multiple myeloma.
    Brünnert D; Kraus M; Stühmer T; Kirner S; Heiden R; Goyal P; Driessen C; Bargou RC; Chatterjee M
    Biochim Biophys Acta Mol Basis Dis; 2019 Jun; 1865(6):1666-1676. PubMed ID: 30954557
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Design, synthesis and biological assay of novel tripeptidic tetrazoles as inhibitors of 20S proteasome].
    Ma YH; Xu B; Cui JR; Yang ZJ; Zhang LR; Zhang LH
    Yao Xue Xue Bao; 2012 Apr; 47(4):472-8. PubMed ID: 22799029
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Design, synthesis, in vitro and in vivo evaluation, and structure-activity relationship (SAR) discussion of novel dipeptidyl boronic acid proteasome inhibitors as orally available anti-cancer agents for the treatment of multiple myeloma and mechanism studies.
    Lei M; Feng H; Bai E; Zhou H; Wang J; Shi J; Wang X; Hu S; Liu Z; Zhu Y
    Bioorg Med Chem; 2018 Aug; 26(14):3975-3981. PubMed ID: 29934218
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Terminal functionalized thiourea-containing dipeptides as multidrug-resistance reversers that target 20S proteasome and cell proliferation.
    Qin JM; Huang RZ; Yao GY; Liao ZX; Pan YM; Wang HS
    Eur J Med Chem; 2017 Jan; 126():259-269. PubMed ID: 27889629
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.